NorthWest Biotherapeutics Inc (NWBO)

[bas2020]

'We're open for business': FDA's Peter Marks says agency ready to review novel cancer vaccines despite unknowns

As new cancer vaccines—led by Moderna and Merck’s mRNA-4157—near pivotal trial readouts, the FDA’s vaccines czar Peter Marks, M.D., Ph.D., said the agency is ready to review the shots despite AI-related unknowns.

“We are ready to review—we’re open for business,” Marks, director of the FDA’s Center for Biologics Evaluation and Research, said of cancer vaccines at the 2024 World Vaccine Congress (WVC).

“We have therapeutic cancer vaccines coming in; I think we would review them very much like we could review potentially a CAR-T cell or other therapeutic products,” Marks said.

Not surprising that the FDA is only focusing on BP with their mRNA approach... as typical.